Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan
SEC Form 4 Filing
Director Juan R. Luciano acquired 17 shares of Eli Lilly common stock at $885.01 per share through a deferral plan.
Summary
- Director Juan R. Luciano acquired 17 shares of Eli Lilly & Co. common stock on June 17, 2024.
- The shares were acquired at a price of $885.01 per share.
- The acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
- The shares will be settled in common stock following the director's separation from service.
- Following the transaction, the director's total holdings are 15,738 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company, which is generally seen as a good sign. However, it's a routine transaction and not a major event.
Positives
- The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
Future Outlook
The acquired shares will be settled in common stock following the director's separation from service.
Industry Context
This is a routine filing related to insider transactions and is common for publicly traded companies. It reflects the compensation structure for board members.
Comparison to Industry Standards
- Director share acquisitions through deferral plans are a common practice among large publicly traded companies, such as those in the pharmaceutical sector like Pfizer and Johnson & Johnson.
- These plans are often used to align the interests of directors with those of shareholders by tying their compensation to the long-term performance of the company.
- The price of $885.01 per share is consistent with the current trading price of Eli Lilly stock.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it shows a director's continued investment in the company.
Key Dates
| Date | Description |
|---|---|
| 06/17/2024 | Date of the share acquisition. |
| 06/18/2024 | Date the form was signed. |
Keywords
Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Insider Trading, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.